01543nas a2200337   4500000000100000008004100001260001300042653001000055653001200065653003100077653001100108653002300119653001200142653000900154653000900163653001600172653002500188653001400213653001300227653001500240100001400255700001700269700001700286245006000303856005900363300001000422490000700432050003200439520072000471022001401191       1991                            d  c1991 Sep10aAdult10aAnimals10aDrug Resistance, Microbial10aHumans10aLeprostatic Agents10aleprosy10aMale10aMice10aMiddle Aged10aMycobacterium leprae10aRifabutin10aRifampin10aRifamycins1 aYoder L J1 aJacobson R R1 aHastings R C00aThe activity of rifabutin against Mycobacterium leprae.  uhttp://leprev.ilsl.br/pdfs/1991/v62n3/pdf/v62n3a06.pdf  a280-70 v62  aInfolep Library - available3 a<p>Minimal effective doses of rifabutin and rifampicin were determined in Mycobacterium leprae isolated from skin biopsies of newly diagnosed, previously untreated lepromatous leprosy patients. Rifabutin was more potent than rifampicin. Our previous report that rifabutin was fully active against rifampicin-resistant M. leprae could not be confirmed. Examination of two strains of rifampicin-resistant M. leprae from elsewhere, and a repeat experiment on our original strain of rifampicin-resistant bacilli, showed full cross-resistance between rifampicin and rifabutin. A clinical trial in three newly diagnosed, previously untreated lepromatous patients showed that rifabutin has rapid bactericidal activity.</p>  a0305-7518